Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
Tweet Send to a Friend
Needham & Company reiterated a Buy rating on CONMED (NASDAQ: CNMD), and raised the price target to $60.00 (from $56.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
